Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKS NASDAQ:BCRX NASDAQ:LGND NASDAQ:RGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$26.97-2.7%$28.23$25.17▼$36.45$4.57B0.531.86 million shs2.48 million shsBCRXBioCryst Pharmaceuticals$7.91-2.0%$8.43$6.01▼$11.31$1.69B1.132.13 million shs3.20 million shsLGNDLigand Pharmaceuticals$165.75-0.8%$146.09$93.58▼$169.49$3.27B0.96153,688 shs298,641 shsRGENRepligen$113.54-5.0%$120.73$102.96▼$182.52$6.72B1.07665,349 shs707,503 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes-2.67%-9.92%-5.80%-9.59%+1.51%BCRXBioCryst Pharmaceuticals-1.98%-4.35%-7.27%-23.72%+2.33%LGNDLigand Pharmaceuticals-0.78%-0.60%+6.24%+47.33%+60.78%RGENRepligen-5.00%-8.85%-10.70%-10.96%-20.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$26.97-2.7%$28.23$25.17▼$36.45$4.57B0.531.86 million shs2.48 million shsBCRXBioCryst Pharmaceuticals$7.91-2.0%$8.43$6.01▼$11.31$1.69B1.132.13 million shs3.20 million shsLGNDLigand Pharmaceuticals$165.75-0.8%$146.09$93.58▼$169.49$3.27B0.96153,688 shs298,641 shsRGENRepligen$113.54-5.0%$120.73$102.96▼$182.52$6.72B1.07665,349 shs707,503 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes-2.67%-9.92%-5.80%-9.59%+1.51%BCRXBioCryst Pharmaceuticals-1.98%-4.35%-7.27%-23.72%+2.33%LGNDLigand Pharmaceuticals-0.78%-0.60%+6.24%+47.33%+60.78%RGENRepligen-5.00%-8.85%-10.70%-10.96%-20.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 2.92Moderate Buy$41.8555.16% UpsideBCRXBioCryst Pharmaceuticals 2.90Moderate Buy$16.70111.13% UpsideLGNDLigand Pharmaceuticals 3.00Buy$176.506.49% UpsideRGENRepligen 2.67Moderate Buy$166.6746.79% UpsideCurrent Analyst Ratings BreakdownLatest BCRX, RGEN, ALKS, and LGND Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025RGENRepligenJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$145.00 ➝ $135.009/9/2025ALKSAlkermesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$43.009/9/2025ALKSAlkermesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$34.00 ➝ $35.009/9/2025ALKSAlkermesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$46.009/3/2025ALKSAlkermesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/3/2025LGNDLigand PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$167.00 ➝ $190.009/3/2025RGENRepligenHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$180.009/2/2025RGENRepligenRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$205.009/2/2025ALKSAlkermesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$44.009/2/2025LGNDLigand PharmaceuticalsBenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$160.00 ➝ $175.008/28/2025LGNDLigand PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$157.00 ➝ $206.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.56B2.86$2.58 per share10.45$9.05 per share2.98BCRXBioCryst Pharmaceuticals$450.71M3.68N/AN/A($2.30) per share-3.44LGNDLigand Pharmaceuticals$167.13M19.44$1.59 per share103.97$43.95 per share3.77RGENRepligen$634.44M10.07$2.95 per share38.47$35.21 per share3.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$367.07M$2.0812.9719.691.5623.15%24.86%17.14%10/23/2025 (Estimated)BCRXBioCryst Pharmaceuticals-$88.88M-$0.18N/AN/A1.83-6.41%N/A-1.78%11/3/2025 (Estimated)LGNDLigand Pharmaceuticals-$4.03M-$4.00N/A44.68N/A-40.44%-9.21%-8.09%11/6/2025 (Estimated)RGENRepligen-$25.51M-$0.25N/A48.112.20-2.05%4.61%3.24%11/11/2025 (Estimated)Latest BCRX, RGEN, ALKS, and LGND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025LGNDLigand Pharmaceuticals$1.54$1.60+$0.06$0.24$43.87 million$47.63 million8/4/2025Q2 2025BCRXBioCryst Pharmaceuticals$0.03$0.15+$0.12$0.02$149.59 million$163.35 million7/29/2025Q2 2025ALKSAlkermes$0.42$0.52+$0.10$0.52$343.20 million$390.66 million7/29/2025Q2 2025RGENRepligen$0.40$0.37-$0.03$0.26$174.62 million$182.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/ABCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/ARGENRepligenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermesN/A3.232.85BCRXBioCryst PharmaceuticalsN/A2.252.22LGNDLigand PharmaceuticalsN/A5.455.21RGENRepligen0.268.597.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%BCRXBioCryst Pharmaceuticals85.88%LGNDLigand Pharmaceuticals91.28%RGENRepligen97.64%Insider OwnershipCompanyInsider OwnershipALKSAlkermes4.40%BCRXBioCryst Pharmaceuticals5.10%LGNDLigand Pharmaceuticals7.00%RGENRepligen1.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes1,800165.08 million157.82 millionOptionableBCRXBioCryst Pharmaceuticals530209.92 million199.21 millionOptionableLGNDLigand Pharmaceuticals8019.60 million18.23 millionOptionableRGENRepligen1,77856.26 million55.58 millionOptionableBCRX, RGEN, ALKS, and LGND HeadlinesRecent News About These CompaniesUnited Services Automobile Association Acquires New Shares in Repligen Corporation $RGENSeptember 13 at 4:27 AM | marketbeat.comWhy Repligen (RGEN) Stock Is Down TodaySeptember 12 at 7:48 PM | msn.comIs There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 29% Undervaluation?September 10 at 5:16 PM | uk.finance.yahoo.comRBC Capital Reaffirms Their Buy Rating on Repligen (RGEN)September 10 at 5:16 PM | theglobeandmail.comFred Alger Management LLC Boosts Position in Repligen Corporation $RGENSeptember 10 at 6:53 AM | marketbeat.comDynamic Technology Lab Private Ltd Raises Stake in Repligen Corporation $RGENSeptember 10 at 6:01 AM | marketbeat.comScientech Research LLC Makes New Investment in Repligen Corporation $RGENSeptember 9, 2025 | marketbeat.comRepligen Corporation $RGEN Shares Sold by Polar Asset Management Partners Inc.September 9, 2025 | marketbeat.comSandler Capital Management Sells 8,004 Shares of Repligen Corporation $RGENSeptember 8, 2025 | marketbeat.comCinctive Capital Management LP Sells 59,424 Shares of Repligen Corporation $RGENSeptember 8, 2025 | marketbeat.comGranahan Investment Management LLC Trims Stake in Repligen Corporation $RGENSeptember 7, 2025 | marketbeat.comEFG Asset Management North America Corp. Has $1.65 Million Stake in Repligen Corporation $RGENSeptember 7, 2025 | marketbeat.comAlliancebernstein L.P. Purchases 13,284 Shares of Repligen Corporation $RGENSeptember 7, 2025 | marketbeat.comAlyeska Investment Group L.P. Boosts Holdings in Repligen Corporation $RGENSeptember 6, 2025 | marketbeat.comRepligen (NASDAQ:RGEN) Given "Buy" Rating at HC WainwrightSeptember 6, 2025 | americanbankingnews.comRepligen (NASDAQ:RGEN) Earns "Buy" Rating from HC WainwrightSeptember 5, 2025 | marketbeat.comAWM Investment Company Inc. Cuts Stock Holdings in Repligen Corporation $RGENSeptember 5, 2025 | marketbeat.comRepligen Corporation $RGEN Stock Holdings Lowered by 12 West Capital Management LPSeptember 5, 2025 | marketbeat.comRepligen Corporation (RGEN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptSeptember 4, 2025 | seekingalpha.comFirst Light Asset Management LLC Has $11.18 Million Stock Holdings in Repligen Corporation $RGENSeptember 4, 2025 | marketbeat.comJump Financial LLC Takes $343,000 Position in Repligen Corporation $RGENSeptember 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 2025Alphabet’s Resurgence: It's Now a Clear Market LeaderBy Ryan Hasson | September 2, 2025BCRX, RGEN, ALKS, and LGND Company DescriptionsAlkermes NASDAQ:ALKS$26.97 -0.74 (-2.67%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$26.96 0.00 (-0.02%) As of 09/12/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.BioCryst Pharmaceuticals NASDAQ:BCRX$7.91 -0.16 (-1.98%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$7.90 0.00 (-0.06%) As of 09/12/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Ligand Pharmaceuticals NASDAQ:LGND$165.75 -1.31 (-0.78%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$165.78 +0.03 (+0.02%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.Repligen NASDAQ:RGEN$113.54 -5.97 (-5.00%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$114.80 +1.27 (+1.11%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
